Aphria achieves next milestone in international expansion strategy
Nov. 23, 2017, Leamington, Ont. - Aphria Inc. has achieved another milestone as part of its expansion strategy, obtaining its Dealer's License pursuant to the Controlled Drugs and Substances Act under Health Canada. This permits the Company to possess, sell and transport medical cannabis oil and resin to international markets.
November 23, 2017 By Aphria
“There is an incredible appetite for high-quality medical cannabis in legal markets around the world. Obtaining our Dealer’s License is a significant milestone in our international expansion strategy as it enables Aphria to have greater control over importing and exporting medical cannabis oil globally,” said Vic Neufeld, CEO of Aphria. “This license will accelerate our speed to international markets and broaden our patient base internationaly, resulting in greater revenue for Aphria.”
As mandated by Health Canada, import and export permits from the relevant international and Canadian regulatory authorities, will be required for all transactions to international markets.
Aphria is well positioned to meet the increasing international demand for medical cannabis in legal markets like Australia, Italy, Germany and Argentina. Aphria is rapidly completing its four-part expansion of its fully-funded facility in Leamington, Ontario, which will increase the greenhouse growing footprint to one million square feet and increase our capacity to supply more than 100,000 kgs of high-quality cannabis at one of the lowest costs in the industry.
Print this page